Lung
REZILIENT2
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Lung Cancer
Study Phase
IIb
Trial Identifiers
GenesisCare Location(s)
Principal Investigator(s)